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Abstract Animal models with high predictive power are a
prerequisite for translational research. The closer the simi-
larityofamodeltoParkinson’sdisease(PD),thehigheristhe
predictivevalueforclinicaltrials.AnidealPDmodelshould
present behavioral signs and pathology that resemble the
human disease. The increasing understanding of PD strati-
ﬁcation and etiology, however, complicates the choice of
adequate animal models for preclinical studies. An ultimate
mousemodel,relevanttoaddressallPD-relatedquestions,is
yet to be developed. However, many of the existing models
are useful in answering speciﬁc questions. An appropriate
modelshouldbechosenafterconsideringboththecontextof
theresearchandthemodelproperties.Thisreviewaddresses
the validity, strengths, and limitations of current PD mouse
models for translational research.
Introduction
Age-related neurodegenerative diseases are an increasing
burden to an aging population. Parkinson’s disease (PD),
the most common neurodegenerative movement disorder,
frequently occurs in an idiopathic form without clearly
deﬁned cause. Familial forms of PD, arising from mono-
genetic mutations, account for a minority of PD cases. The
clinical course of both idiopathic and familial forms of PD
is believed to be inﬂuenced by environmental and genetic
risk factors. Mouse models are powerful tools in PD
translational research. However, an appropriate model
should be chosen after considering both the model char-
acteristics and the research context.
The Parkinson’s disease puzzle
PD is a progressive neurodegenerative disorder clinically
characterized by the cardinal symptoms of resting tremor,
bradykinesia, cogwheel rigidity, and postural instability
(Jankovic 2008). Responsiveness to L-3,4-dihydroxyphen-
ylalanine (L-DOPA) and brain imaging distinguish PD
from other disorders (D’Costa et al. 1995; Isaias and
Antonini 2010). The pathological hallmarks of PD are loss
of dopaminergic cells in the substantia nigra pars compacta
and subsequent loss of dopamine innervation in the stria-
tum (Forno 1996). Motor symptoms are the most obvious
consequence of this nigrostriatal neurodegeneration.
However, not only the basal ganglia but also other parts of
the central nervous system as well as the autonomic ner-
vous system are affected. A wide range of resulting non-
motor symptoms can affect the patient’s quality of life
(Langston 2006; Lees 2009). It has been assumed that at
least some subforms of PD start not with motor but non-
motor symptoms such as hyposmia, rapid eye movement
sleep behavior disorder (RBD), constipation, depression,
reduced cardiac [
123I]metaiodobenzylguanidine (MIBG)
uptake, and, possibly, reduced color discrimination
(Chaudhuri et al. 2006; Fujishiro et al. 2008; Hawkes
2008; Katzenschlager and Lees 2004). There is also a
broad consensus that neurodegenerative processes in PD
start many years before the actual onset of clinical
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not yet fully understood sequential plan underlying PD
pathogenesis seems to correlate with clinical and patho-
logical features (Hawkes et al. 2010). Lewy bodies, the
histological hallmarks of PD, are a-synuclein-positive
intracellular inclusions that are already present during the
prodromal phase (Fearnley and Lees 1991). A yet asymp-
tomatic, incidental Lewy body disease has been proposed
(Markesbery et al. 2009). However, it is not yet fully
understood if Lewy bodies have more protective or more
destructive effects. Motor symptoms start only in the late
phase of nigrostriatal degeneration, when 50–80% of nigral
dopaminergic neurons are already lost (Bezard et al. 2001;
Braak et al. 2003; Greffard et al. 2006). At this stage,
nonmotor features remain frequent and clinically signiﬁ-
cant because they largely contribute to impaired quality of
life and shortened life expectancy. Neuroprotective treat-
ments are not yet available but are one of the priorities in
current PD research. However, reliable biomarkers for
early diagnosis and disease state identiﬁcation are not yet
available (Gasser 2009a; Schapira et al. 2009).
Consequently, at present, the diagnosis of PD is based on
the above-mentioned characteristic clinical motor features.
Importantly, the currently recognized monogenic familial
forms of PDdonotdemonstrate the sameclinicalfeaturesas
those of sporadic late-onset forms of PD. Genetic forms can
present more pronounced psychiatric features and lack
nonmotor symptoms. Nevertheless, the phenotypical over-
lapping between familial and idiopathic PD is sufﬁcient to
dissect the commonly involved pathways. These include
mitochondrial dysfunction, oxidative stress, protein mis-
folding, protein degradation, protein aggregation, and
inﬂammation (Schapira and Tolosa 2010). Evidently, a
better understanding of the molecular basis of PD will open
new routes to diagnosis and therapy (Pienaar et al. 2008;
Robinson 2010). On the other hand, it will inﬂuence the
choice of adequate models for translational research.
Animal models for translational research in PD
Progress in understanding the etiology of PD has provided
candidate targets for neuroprotective and neurorescue
interventions. However, until now, no potential protective
treatment has received regulatory approval (Rascol 2009).
One reason for this is the lack of good PD animal models
for preclinical translational research. Animal models
should fulﬁll speciﬁc requirements for the testing of neu-
roprotective therapies for PD. First, the model should
induce reproducible nigral lesions. Second, the loss of
dopaminergic neurons should be stable, without spontane-
ous recovery. Third, the model should provide a time
window for the application of potential neuroprotective
therapies (Emborg 2004). Ideally, a successful neuropro-
tective agent should prevent further behavioral changes,
progressive biochemical deﬁcits, and neurodegeneration.
Thus, neuroprotection requires intervention when there are
still cells left to be protected. Later interventions should be
regarded as restorative strategies.
Current status and remaining challenges
Arvid Carlsson’s research led to the development of
L-DOPA-based treatments (Andersen 2009). Today,
L-DOPA remains the gold standard treatment for PD.
However, the drug has a wide range of adverse effects,
most notably motor ﬂuctuations and dyskinesias. Pharma-
cological strategies that avoid pulsatile dopaminergic
stimulation have a substantial ameliorative effect on these
syndromes. Despite these advances, disease progression
remains unaffected (Lang and Obeso 2004). Finally, deep
brain stimulation is the most recent symptomatic treatment
that continuously and substantially reduces parkinsonian
motor symptoms, whereas gait deterioration and nonmotor
features continue to progress (Hamani et al. 2010).
Despite these therapeutic advances, PD patients con-
tinue to suffer from a severe reduction in quality of life.
The development of interventions to stop or slow disease
progression is therefore a major goal (Schapira and Tolosa
2010). The progress of this endeavor requires a better
understanding of disease etiology and subtype stratiﬁcation
(Rajput et al. 2009). Importantly, early diagnosis enables
the initiation of neuroprotective or other therapeutic
interventions at less advanced stages of the disease.
Current mouse models for PD
PD mouse models are expected to closely match human
pathology. The most important signs to replicate are motor
symptoms, Lewy body formation, neuronal cell loss in the
basal ganglia, age-related disease progression, and non-
motor symptoms. None of the current models satisﬁes all of
these criteria. However, many models fulﬁll a subset.
Empirical choices of adequate models to answer speciﬁc
questions in translational research need to consider, case by
case, the model-speciﬁc advantages and limitations.
Pharmacological and neurotoxic PD models
Reserpine
One of the earliest developed PD models was the phar-
macological reserpine model, which prevents the storage of
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123dopamine in presynaptic terminals, resulting in dopamine
depletion in the striatum (Carlsson et al. 1957; Steg 1964).
Reserpine rabbit models helped to elucidate the critical role
of dopamine in the pathogenesis of PD. This ﬁnding led to
the discovery of dopaminergic drugs such as L-DOPA.
Despite this groundbreaking success, the reserpine model
has signiﬁcant limitations. Reserpine does not exclusively
deplete dopamine and norepinephrine but all monoamines
in a transient fashion. Another limitation of this model is
that transient depletion does not mirror the progressive
dopamine depletion in PD. In addition, the reserpine model
does not reﬂect the histopathology of PD.
6-Hydroxydopamine (6-OHDA)
A few years after publication of the reserpine model, in the
1960s, nigrostriatal pathology was recognized as a primary
factor for PD. In this context, the ﬁrst neurotoxic models,
aiming to reproduce nigrostriatal pathology, were estab-
lished (Table 1). One neurotoxin found to induce PD was
the dopamine analog 6-OHDA (Ungerstedt et al. 1974).
6-OHDA can be taken up into dopaminergic terminals via
dopamine transporters. Inside the cell, it is metabolized,
resulting in the production of hydrogen peroxide and free
radicals, which induce neuronal death via mitochondrial
dysfunction. 6-OHDA cannot cross the blood–brain barrier
and therefore needs to be directly delivered to the brain.
Ungerstedt et al. (1968) studied unilateral 6-OHDA lesions
of the nigrostriatal pathway. By varying the position and
extent of the lesion, different stages of human PD could be
modeled. However, the 6-OHDA model has considerable
limitations as well. It is a dopamine transporter-speciﬁc
model and does not affect any other neurotransmitter.
Therefore, it does not replicate the full spectrum of clinical
signs of human PD, i.e., the degeneration of the locus
coeruleus with local depletion of norepinephrine is not
replicated. In addition, the 6-OHDA-induced acute and
local degeneration does not mirror the slow and extensive
progression of neurodegeneration of the human disease.
Finally, although lesioned animals show some of the cel-
lular and behavioral deﬁcits seen with the human disease,
6-OHDA-treated animals fail to develop Lewy bodies or
a-synuclein-positive inclusions.
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)
In another model involving selective targeting of dopami-
nergic neurons in the brain, PD features are induced after
administration of MPTP. The validity of the MPTP model
is supported by the fact that MPTP exposure is a known,
albeit rare, cause of drug-induced parkinsonism in humans
(Davis et al. 1979; Langston et al. 1983). In mice, MPTP is
typically administered systemically. MPTP is taken up
primarily by astrocytes and converted to its metabolite
MPP?. Then, it is taken up by dopaminergic neurons,
where it exerts toxic effects. Interestingly, loss of dopa-
minergic neurons is observed not only in the basal ganglia
but also in the enteric nervous system (Anderson et al.
2007). Varying regimens of MPTP delivery can produce
varying degrees of nigrostriatal dysfunction. Acute dosing
can produce lesions that result in mild to moderate cell
loss, mimicking cell loss in early stages of human PD.
Chronic dosing, consisting of long series of low-dose
injections, results in more robust lesions representative
of later stages of PD (Bezard et al. 1997). The MPTP
mouse model has been invaluable in understanding the
Table 1 Pharmacological and toxicological models for Parkinson’s disease
Molecule Administration Level of relevance Target I MS NMS TH BG SP Age Ref
6-hydroxydopamine
(6-OHDA)
Local Derivate of
dopamine
Causes oxidative stress after uptake
by dopamine transporters
N Y NR Y Y N N 1
1-methyl-4-phenyl-
1,2,3,4-
terahydropyridine
(MPTP)
Systemic Known, albeit rare,
cause of drug-
induced
parkinsonism in
humans
Taken up by astrocytes primarily,
converted to MPP?, which can be
taken up by dopaminergic neurons,
where it exerts toxic effects
YY Y Y Y D DY 2
Rotenone Systemic Organic pesticide Elicits mitochondrial dysfunction in a
dopamine transporter independent
fashion
Y Y NR Y Y DD NR 3
Paraquat, combined
with maneb
Systemic Paraquat is a
pesticide, maneb
is a fungicide
Causes redox cycling and thereby
oxidative stress
Y Y NR Y Y DD NR 4
Age = age-related progression; BG = neurodegeneration in the basal ganglia; DD = dose-dependent; I = a-synuclein positive inclusions;
MS = motor signs; N = no; NMS = nonmotor signs; NR = not reported; SP = slow progression; TH = reduced level of tyrosine hydroxylase;
Y = yes
References (Ref): 1 = Ungerstedt et al. 1974;2= Anderson et al. 2007; Bezard et al. 1997; Davis et al. 1979; Irwin et al. 1992; Langston et al.
1983;3= Betarbet et al. 2000;p .4= Manning-Bog et al. 2002; Thiruchelvam et al. 2000
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123mechanisms underlying MPTP toxicity. However, despite
robust replication of motor dysfunction and considerable
preclinical successes in the screening for potentially ther-
apeutic drugs, including coenzyme Q10, isradipine CR, and
simvastatin (Beal et al. 1998; Ghosh et al. 2009; Meredith
et al. 2008), the MPTP model has its limitations. For
instance, mice may recover spontaneously after MPTP
lesioning, thus hindering the assessment of therapeutic
efﬁcacy. The variability of MPTP sensitivity between
distinct mouse strains and species is also problematic
(Giovanni et al. 1994a, b; Sedelis et al. 2003). Studies on
primates have demonstrated clear-cut parkinsonian features
as well as protein aggregation after MPTP exposure.
Consequently, this primate MPTP model has served as an
adequate model for translational research toward the
development and optimization of deep-brain stimulation
therapies. In contrast, the MPTP model is less valid with
other species, although as alluded above, the application of
simvastatin in the MPTP mouse model produced interest-
ing results in terms of protection against exotoxins (Ghosh
et al. 2009).
Rotenone
The success of MPTP in replicating the neuropathology of
human PD has led to the examination of other potential
neurotoxin models for PD. Two promising models to
emerge are the rotenone model and the combined paraquat/
maneb model. Rotenone is an organic pesticide that
inhibits complex I of the electron transport chain. It causes
mitochondrial dysfunction and ultimately leads to cell loss
in the nigrostriatal pathway (Betarbet et al. 2000). Rote-
none can be delivered systemically via intranigral infusion
or via gastric gavage to replicate human disease initiation
in enteric neurons, as proposed by Braak (Braak et al.
2003). Rotenone exerts its effects in a dopamine trans-
porter-independent fashion, thereby eliciting mitochondrial
dysfunction in nondopaminergic systems as well. Never-
theless, its neurotoxic effects are predominantly dopamine
neuron-selective. Data from cell culture experiments sug-
gest that rotenone triggers intracellular dopamine release,
which could in turn explain the toxic effect on dopami-
nergic neurons (Inden et al. 2011). However, the variability
of sensitivity between individuals and species and the
potential of this toxin to induce widespread systemic tox-
icity (Ravenstijn et al. 2008) complicates the use of the
rotenone model for translational research.
Paraquat/maneb
Paraquat is a pesticide that is ﬁrst converted to a cation
before being reoxidized. This reaction produces superoxide
radicals, which in turn cause further redox cycling and
oxidative stress. Paraquat is frequently administered in
combination with maneb, a fungicide that has been linked
to the development of parkinsonian symptoms in humans
(Thiruchelvam et al. 2000). Exposure of rodents to a
combination of paraquat and maneb results in signiﬁcant
nigral cell loss and nigral a-synuclein-positive inclusions.
Rats prenatally exposed to maneb show increased sensi-
tivity to paraquat toxicity in adulthood. These observations
support the multihit hypothesis of PD, which suggests that
early insults can sensitize the nigrostriatal system to sub-
sequent hits in adulthood (Thiruchelvam et al. 2000).
Trichloroethylene
Trichloroethylene (TCE), a solvent widely used as a
degreasing agent, is also considered an environmental risk
factor for PD (Gash et al. 2008; Goldman 2010). Peritoneal
administration of TCE causes dopaminergic neuronal cell
death in mice (Guehl et al. 1999). In rats, oral adminis-
tration of TCE induces key features of PD, i.e., loss of
nigral dopaminergic neurons, reduced mitochondrial com-
plex I activity, oxidative stress, microglial activation, and
a-synuclein accumulation (Liu et al 2010a, b). However,
the relevance of this model for translational research
remains to be evaluated.
Overall, pharmacological and neurotoxic models help to
understand the consequences of striatal dopamine loss and
to develop current dopaminergic therapies (Bove et al.
2005). A major limitation of toxin-induced models, how-
ever, is that they do not reproduce the complete spectrum
of human pathology. Although they are excellent for
evaluating the role of the nigrostriatal system in PD and
may be adequate for testing restorative therapeutic com-
pounds, most of these models are limited in their ability to
replicate important aspects of human PD such as its pro-
gressive nature and Lewy body formation.
Genetic models for PD
In the last decade, considerable advances have been made
in the identiﬁcation of genes responsible for monogenic
familial PD. Since 1998, 14 different genes have been
identiﬁed to cause familial PD (Schapira 2006; Schapira
and Tolosa 2010). In addition, recent genome-wide asso-
ciation studies (GWAS) led to the identiﬁcation of yet
another set of risk-associated genes. Besides its role in
familial PD, a-synuclein is, worldwide, the most common
risk factor for idiopathic PD (Pankratz et al. 2009; Satake
et al. 2009). Strong association signals were also identiﬁed
at the MAPT and LRRK2 loci (Simon-Sanchez et al. 2009).
Other important risk factors for PD are mutations in the
glucocerebrosidase gene (Sidransky et al. 2009). A more
404 P. M. A. Antony et al.: Parkinson’s disease
123recently identiﬁed risk factor for PD, named PARK16,
is associated with reduced risk for PD (Tan et al. 2010).
Most recently, ﬁve additional PD risk factors have been
reported: ACMSD, STK39, MCCC1/LAMP3, SYT11, and
CCDC62/HIP1R (International Parkinson Disease Geno-
mic Consortium 2011). As PD appears to be a complex
genetic disease sensitive to environmental factors, the
discovery of genetic factors in PD led to a new generation
of PD models: the genetic PD mouse models.
a-Synuclein models
The very ﬁrst identiﬁed mutations leading to familial PD
were located in the gene encoding a-synuclein (Chartier-
Harlin et al. 2004; Ibanez et al. 2004; Kruger et al. 1998;
Polymeropoulos et al. 1997). In addition to single nucleo-
tide polymorphisms (SNPs), rare triplications and dupli-
cations of the a-synuclein gene (SNCA) were reported in
human PD (Ahn et al. 2008; Gasser 2009b; Singleton et al.
2003). However, a-synuclein, which typically accumulates
in Lewy bodies (Spillantini et al. 1998), is not mutated in
the large majority of PD patients. Nevertheless, numerous
lines of mice overexpressing a-synuclein have been gen-
erated using distinct promoters and transgenes (Fernagut
and Chesselet 2004). These models use transgenes with
mutations causing familial PD, the full-length protein, or
truncated forms of the protein. Most recapitulate some but
not all aspects of PD, and effects relevant to the disease are
generally correlated to the levels of a-synuclein expression
(Magen and Chesselet 2010). Importantly, expression of
transgenes is not limited to dopaminergic neurons but is
deﬁned by the nature of the genetic modiﬁcation, i.e.,
promoter and genomic insertion site. However, a common
advantage of these models, compared to pharmacological
and toxicological models, is the slowly progressive accu-
mulation of a-synuclein, a typical feature of idiopathic PD.
The main strength of a-synuclein models is the ability
to replicate a-synuclein-positive inclusions (Table 2),
although the typical ﬁbrillar halo structure of Lewy bodies,
observed in human PD, is not observed in the murine
a-synuclein-positive inclusions (Maries et al. 2003). A
major limitation of a-synuclein models is their inability to
model cell loss in the substantia nigra pars compacta. Mice
overexpressing wild-type human a-synuclein exhibit
reduced olfaction, autonomic dysfunction, a-synuclein
accumulation, and early motor deﬁcits in the absence of
nigrostriatal neurodegeneration (Chesselet et al. 2008;
Fleming et al. 2004; Fleming et al. 2008; Rockenstein et al.
2002).
a-Synuclein knockout mice are viable and show
decreased striatal dopamine levels and reduced rearing.
These ﬁndings may be explained by the hypothesis that
a-synuclein plays a role in synaptic vesicle function. Triple
abc-synuclein knockout mice present age-dependent syn-
aptic and neuronal dysfunction, demonstrating that synu-
cleins contribute to the long-term operation of the nervous
system (Burre et al. 2010; Greten-Harrison et al. 2010).
Conversely, mice overexpressing a-synuclein develop
intraneuronal inclusions and show decreased striatal
dopamine levels, despite lacking nigral cell loss. However,
mice overexpressing a double-mutated or a truncated form
of a-synuclein under the tyrosine hydroxylase (TH) pro-
moter present a selective loss of nigrostriatal dopaminergic
neurons. The double-mutated a-synuclein variant (A30P/
A53T) used in one of these studies has never been
described in humans (Thiruchelvam et al. 2004). In con-
trast, expression of N-terminal a-synuclein fragments,
comparable to those used in the second study (Wakamatsu
et al. 2008a), has been detected in PD brain extracts (Li
et al. 2005). In addition, the relevance of the A53T muta-
tion in mouse models remains to be evaluated. Although
the A53T mutation can cause PD in humans, threonine is
the wild-type residue at this position in the murine
sequence (Cabin et al. 2005; Larsen et al. 2009). Human
A53T a-synuclein, however, was described to be more
toxic on an a-synuclein-null background than on a murine
wild-type background. This contrast between the protective
effects of wild-type mouse a-synuclein and the deteriora-
tive effects of human A53T a-synuclein on mice might be
linked to the six other a-synuclein amino acid differences
between these two species (Cabin et al. 2005).
Recently, data from tyrosine hydroxylase (TH) pro-
moter-controlled a-synuclein-overexpressing mouse mod-
els led to the hypothesis that microglial activation is an
early hallmark of PD (Su et al. 2008, 2009). Findings at the
neurochemical and gene expression level suggest that
a-synuclein also inﬂuences dopamine metabolism (Miller
et al. 2007; Richﬁeld et al. 2002; Yu et al. 2008). In
addition, TH promoter-controlled overexpression of the
double-mutated a-synuclein impairs the ubiquitin protea-
some system in aged mice (Chen et al. 2006). The main
limitation of this model is a spatially restricted pathology.
This limitation can be circumvented, at least in part, by
crossing a-synuclein transgenic mice with mice lacking
murine a-synuclein. In this case, the absence of endoge-
nous a-synuclein appears to drive the aggregation of
transgenic a-synuclein throughout different brain regions
(Prasad et al. 2011). In contrast, human Lewy body for-
mation and a-synuclein expression in neurites are widely
distributed in both the central and peripheral nervous sys-
tems (Braak et al. 2003; Halliday et al. 2005).
Platelet-derived growth factor-b (PDGF-b) promoter-
controlled a-synuclein-overexpressing mouse models aim
to mimic the broad distribution of a-synuclein pathology in
humans (Masliah et al. 2000). Recent ﬁndings suggest that
overexpression of A53T a-synuclein affects neurogenesis
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Model(s) Promoter Background I MS NMS TH BG SP Age Ref
WT, A53T PDGF-b C57BL/6 9 DBA2 Y Y NR Y Y NR Y 1
WT KO C57BL/6 NR NR NR NR NR NR NR 2
WT PDGF-b C57BL/6 NR NR NR NR NR Y NR 3
A53T Mouse Thy-1 C57BL/6 LN Y NR NR N NR NR 4
WT, A30P, A53T Mouse Thy-1 C57BL/6 Y Y IFC NR Y NR Y 5
WT, (A30P) Mouse Thy-1 C57BL/6 9 DBA2 Y Y Y YYYN 6
Y39C Mouse Thy-1 FVB/N Y Y CD NNYY 7
A30P ? A53T Human Thy-1 C57BL/6 9 DBA2 Y Y N YYYN 8
(WT), (A30P), A53T Mouse prion C3H/HeJ 9 C57BL/6J
backcrossed into C57BL/6J
PARKIN KO
YYM DNYNY 9
WT, A53T Mouse prion C57BL/6 9 C 3 H YYR ANYYN 1 0
(WT), A53T Mouse prion FVB/N, FVB 9 129,
a-synuclein KO
N Y NR NR NR Y N 11
(WT), A30P Mouse prion C57BL/6J 9 DBA2
backcrossed into C57BL/6J
N Y ASP N NR NR Y 12
WT, A30P, A53T Hamster prion C57BL/6J 9 SJL N Y NR N NR Y Y 13
WT, A30P, A53T Rat THP Swiss Webster 9 C57BL/DBA N NR NR N NR NR NR 14
WT, A30P ± A53T Rat THP C57BL/6J N Y NR NR NR Y Y 15
Truncated (1-120) Rat THP C57BL/6J 9 CBA/ca
backcrossed into C57BL/6J,
a-synuclein KO
Y Y NR NR N Y Y 16
Truncated (1-130) Rat THP C57BL/6J N N REB YYNN 1 7
A30P ? A53T Chicken beta actin, BA C57BL/6 NR NR MD N N NR Y 18
A30P ? A53T Mouse THP C57BL/6 NR NR MD N N NR Y 19
A30P ? A53T Mouse prion C57BL/6 NR NR NR NR N NR NR 20
WT, A30P, A53T CaM-tTA (tet-off) C57BL/6 (WT and A30P),
C57BL/CH3 (WT and A53T)
N Y CD NR Y Y Y 21
A30P KI in endogenous
a-synuclein
C57BL/6 NR Y NR RD NR Y Y 22
Truncated (1-119) Conditional ROSA26 C57BL/6J N NR NR RD N NR N 23
A53T Conditional ROSA26 C57BL/6J N NR NR NR N NR N 23
WT, A30P, A53T Endogenous
a-synuclein (BAC)
FVB/N 9 129S6/SvEvTac N Y Y NS N Y N 24
Alpha-synuclein models express truncated or full-length a-synuclein with or without mutations. The expression of these constructs, in different
mouse strains, is controlled by different promoters and causes distinct phenotypes. The models are grouped by project. Lines with a stronger
phenotype are underlined and lines without phenotype are in parentheses
Age = age-related progression; ASP = affected synaptic plasticity; BA = beta-actin promoter; BG = neurodegeneration in the basal ganglia;
CD = cognitive deﬁcits; I = a-synuclein positive inclusions; IFC = impaired fear conditioning; LN = Lewy-like neurites; MD = mitochon-
drial deﬁcits; MS = motor signs; N = no; NMS = nonmotor signs; NR = not reported; NS = not signiﬁcant; RA = reduced anxiety;
RD = reduced dopamine level; REB = reduced exploratory behavior; SP = slow progression; TH = reduced level of tyrosine hydroxylase;
THP = tyrosine hydroxylase promoter; Y = yes
References (Ref): 1 = Hashimoto et al. 2003; Koob et al. 2010; Masliah et al. 2000; Rockenstein et al. 2002; Winner et al. 2004; Winner et al.
2008; Yacoubian et al. 2008;2= Sharon et al. 2003;3= Liu P et al. Liu et al. 2010a, b;4= van der Putten et al. 2000;5= Frasier et al. 2005;
Freichel et al. 2007; Kahle et al. 2000; Neumann et al. 2002; Poon et al. 2005; Schell et al. 2009;6= Fernagut et al. 2007; Fleming et al. 2004;
Fleming et al. 2006; Fleming et al. 2008; Koob et al. 2010; Rockenstein et al. 2002; Song et al. 2004; Wang et al. 2008; Watson et al. 2009;W u
et al. 2010;7= Zhou et al. 2008;8= Ikeda et al. 2009; Ono et al. 2009;9= Lee et al. 2002; Martin et al. 2006; Miller et al. 2007; Unger et al.
2006; von Coelln et al. 2006;1 0= Gao et al. 2008; George et al. 2008; Giasson et al. 2002; Graham and Sidhu 2010; Norris et al. 2007; Sotiriou
et al. 2010;1 1= Cabin et al. 2005; Gispert et al. 2003;1 2= Gureviciene et al. 2007; 2009; Oksman et al. 2009; Yavich et al. 2006;
Yavich et al. 2005;1 3= Gomez-Isla et al. 2003; Nieto et al. 2006;1 4= Manning-Bog et al. 2003; Matsuoka et al. 2001; Yu et al. 2008;
15 = Chen et al. 2006; Miller et al. 2007; Richﬁeld et al. 2002; Su et al. 2009; Su et al. 2008; Thiruchelvam et al. 2004;1 6= Tofaris et al. 2006;
17 = Wakamatsu et al. 2008a; Wakamatsu et al. 2008b;1 8= Maskri et al. 2004; Stichel et al. 2007;1 9= Maskri et al. 2004; Stichel et al.
2007;2 0= Maskri et al. 2004;2 1= Lim et al. 2010; Marxreiter et al. 2009; Nuber et al. 2008;2 2= Plaas et al. 2008;2 3= Daher et al. 2009;
24 = Kuo et al. 2010
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123and proliferation of newly born neurons in the subven-
tricular zone (Winner et al. 2004, 2008). Molecular anal-
ysis of mice with PDGF-b-controlled overexpression of
a-synuclein suggested that interactions between a-synuc-
lein, polyunsaturated fatty acids, and cholesterol accelerate
a-synuclein aggregation (Bieschke et al. 2006; Sharon et al.
2003). Koob et al. (2010) used this model to show that
treatment with the cholesterol synthesis inhibitor lovastatin
alleviates these alterations. In PDGF-b/a-synuclein mice,
gene expression is altered. However, neuronal death has
not yet been reported in these mice (Yacoubian et al. 2008).
Changes due to overexpression of a-synuclein are restricted
mainly to the olfactory bulb and the hippocampus, and
deﬁcits occur relatively late. Despite changes at the gene
expression level, dopamine metabolism, TH terminals, and
neurogenesis, no overt pathology of the nigrostriatal sys-
tem or clinical hallmarks have been observed in PDGF-b/
a-synuclein mice.
In contrast to PDGF-b/a-synuclein models, prion protein
promoter a-synuclein models aim to study the effects of
extremely high overexpression of a-synuclein in neurons
usually involved in PD, including neurons of the substantia
nigra (Maskri et al. 2004). However, the translational rel-
evance of these models, with typically severe motor deﬁ-
cits, is mitigated by high transgene expression in motor
neurons of the spinal cord and brainstem, which confer
behavioral deﬁcits that are not characteristic for PD
(Magen and Chesselet 2010). An additional drawback is
the lack of cell loss in the substantia nigra and locus
coeruleus.
Compared to the prion protein promoter, the Thy-1
promoter causes a more widespread expression of a-syn-
uclein, which is not restricted to catecholaminergic neurons
(Rockenstein et al. 2002), and does not cause any motor
neuron loss when used in C57BL/6 mice. Nigral cell loss
was observed in only a few cases, but most of the studies
found typical PD phenotypes such as loss of dopamine in
the striatum, motor deﬁcits, and nonmotor deﬁcits (Flem-
ing et al. 2004; Ikeda et al. 2009; Ono et al. 2009; van der
Putten et al. 2000). These mice further develop an age-
dependent neurite terminal a-synuclein pathology, sug-
gesting that a-synuclein is selectively phosphorylated in
restricted brain regions (Schell et al. 2009). Some Thy1/
a-synuclein mouse lines present early motor and nonmotor
deﬁcits equivalent to those in PD prior to clinical diagno-
sis, suggesting that these models could be useful for the
study of preclinical PD stages and hence for translational
research (Fernagut et al. 2007; Fleming et al. 2004, 2006,
2008; Koob et al. 2010; Song et al. 2004). However, other
studies using Thy1/a-synuclein mouse lines demonstrated a
much later onset, or even absence, of motor dysfunction
(Freichel et al. 2007; Neumann et al. 2002; Zhou et al.
2008).
Models overexpressing a-synuclein under the calcium/
calmodulin-dependent protein kinase IIa (CaM) promoter
were initially designed to study postnatal neurogenesis in
the olfactory bulb and hippocampus. Conditional overex-
pression driven by the CaM promoter can be triggered by a
tetracycline transactivator. The emergence of conditional
transgenic models enables detailed investigation of the
reversibility of a-synuclein pathology, thereby helping to
focus on therapeutic strategies that aim to regulate a-syn-
uclein expression at early stages of the disease (Lim et al.
2010; Marxreiter et al. 2009; Nuber et al. 2008). Recent
models allow the control of gene expression in a region-
dependent manner. One example is the Cre/loxP-based
mouse model—expressing truncated N-terminal a-synuc-
lein fragments—that shows reduced striatal dopamine
levels but no neurodegeneration (Daher et al. 2009).
The most recently reported a-synuclein mouse model
expresses A53T a-synuclein under a P1 artiﬁcial chromo-
some on an a-synuclein-null background. These mice have
early motor deﬁcits but no a-synuclein-positive inclusions,
no loss of TH-positive cells in the substantia nigra, and no
dopamine loss in the striatum. However, these mice have
decreased colonic motility that may result from proteinase
K-resistant a-synuclein aggregates found in neurons of the
enteric nervous system. Olfactory function and cardiac
innervation remain intact (Kuo et al. 2010). Consistently,
this model could serve to investigate therapies for gastro-
intestinal dysfunction in early preclinical PD stages.
PARKIN, PTEN-induced putative kinase 1 (PINK1),
and DJ1
In addition to the a-synuclein model, other models of
familial PD have been reported. Recessive mutations in
PARKIN, PINK1, and DJ1 were mostly modeled using
knockout strategies that result in the lack of the corre-
sponding protein and, so far, to modest PD-associated
deﬁcits (Table 3).
The most frequent mutations causing early-onset
recessive familial forms of PD occur in the PARKIN gene.
PARKIN is an ubiquitin E3 ligase that ubiquitinates pro-
teins to regulate a variety of cellular processes. Loss of E3
ligase activity is thought to play a pathogenic role in both
inherited and sporadic PD (Dawson and Dawson 2010).
More recently, PARKIN has been demonstrated to play a
role in maintaining mitochondrial homeostasis through
targeting damaged mitochondria for mitophagy (Tanaka
2010). PARKIN loss-of-function could thus lead to
enhanced presence of dysfunctional mitochondria, a pro-
cess that could contribute to PD pathogenesis. PARKIN
knockout mice have been generated by deleting either exon
3 or 7. These lines show mild, progressive motor deﬁcits
and premotor signs typical of PD, i.e., reduced dopamine
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123release, synaptic anomalies, mitochondrial damage, and
increased oxidative stress. However, none of these models
shows a progressive loss of nigrostriatal dopaminergic
neurons (Goldberg et al. 2003; Itier et al. 2003; Martella
et al. 2009; Palacino et al. 2004; Periquet et al. 2005;
Rodriguez-Navarro et al. 2007; Stichel et al. 2007; Von
Coelln et al. 2004; Zhu et al. 2007). Dopaminergic cell loss
can be induced by exposure to the inﬂammatory stressor
lipopolysaccharide (LPS) (Frank-Cannon et al. 2008),
illustrating that PARKIN mutations may make dopami-
nergic neurons more vulnerable to environmental insults.
Lu et al. (2009) investigated whether the PARKIN mutation
Q311X exerts dominant toxicity on nigrostriatal dopami-
nergic neurons. The selective expression of this mutation in
dopaminergic neurons does indeed cause progressive
nigrostriatal dopaminergic cell loss, a-synuclein pathology,
and motor deﬁcits (Lu et al. 2009). This implies that these
mice provide a model for dopaminergic neuron death
caused by PARKIN mutations.
Similar to PARKIN knockout mice, PINK1 and DJ1
mice have, so far, failed to reproduce canonical PD deﬁcits.
Similar observations were made in a triple transgenic
model lacking PARKIN, PINK1, and DJ1 (Kitada et al.
2009). Without additional insults, PINK1 and DJ1 deﬁ-
ciency does not cause spontaneous loss of nigrostriatal
dopaminergic neurons (Aron et al. 2010; Morais et al.
2009). However, most of these mice show reduced activity,
increased oxidative stress, and increased vulnerability to
mitochondrial toxins (Chen et al. 2005; Gautier et al. 2008;
Gispert et al. 2009; Kim et al. 2005). Overall, recessive PD
models appear to have potential for the modeling of envi-
ronmental factors in familial forms of PD.
Leucine-rich repeat kinase 2 (LRRK2)
Dominant LRRK2 mutations have recently been identiﬁed
as causes of familial PD. Heterozygote carriers can develop
familial PD with characteristics similar to the sporadic
disease forms (Cookson et al. 2008). However, penetrance
is strongly age-dependent. At the age of 69 years, only
51% of carriers show signs of PD (Healy et al. 2008).
Several mutations have been identiﬁed in human PD
patients, the most frequent one being the G2019S mutation.
Lin et al. (2009) generated LRRK2 knockout mice and
transgenic mice with inducible overexpression of the
human wild-type, the G2019S mutant, or the kinase
domain-deleted LRRK2. Neither deletion nor overexpres-
sion of these LRRK2 constructs caused gross neurodegen-
eration. However, all three LRRK2 constructs exacerbated
the progression of human A53T a-synuclein-induced neu-
ropathology. Overexpression of LRRK2 or its mutants
impaired the structure and function of the Golgi complex
and microtubule-based transport, resulting in a pathogenic
somatic accumulation of a-synuclein (Lin et al. 2009).
Later, Li et al. (2010) characterized two bacterial arti-
ﬁcial chromosome (BAC) transgenic mouse strains over-
expressing either wild-type or G2019S-mutated LRRK2.
Transgenic mice overexpressing wild-type LRRK2 pre-
sented an elevated striatal dopamine release, were hyper-
active, and showed enhanced motor performance. In
contrast, mice expressing the G2019S mutant showed an
age-dependent decrease in striatal dopamine content (Li
et al. 2010). Melrose et al. (2010) also reported impaired
dopaminergic neurotransmission in BAC LRRK2 mice. In
G2019S mice, these changes were linked to a modiﬁed
localization and phosphorylation of the microtubule-bind-
ing protein tau (Melrose et al. 2010). A more recent study
that also used mice that overexpress G2019S LRRK2 by
using a BAC construct, analyzed adult neurogenesis
(Winner et al. 2011). The proliferation and survival of
newly generated cells was signiﬁcantly decreased by the
overexpression of G2019S LRRK2, and newly generated
neurons exhibited reduced dendritic arborization and fewer
spines (Winner et al. 2011).
Mice harboring the R1441G mutation develop a strong
behavioral phenotype and an altered dopamine release (Li
et al. 2009). In contrast, mice harboring the R1441C
mutation do not present prominent motor defects but only
dopaminergic deﬁcits (Tong et al. 2009). LRRK2 seems to
be involved in both familial and idiopathic PD. Therefore,
LRRK2 is a very attractive target for therapeutic inter-
vention (Paisan-Ruiz et al. 2004; Satake et al. 2009;
Simon-Sanchez et al. 2009; Zimprich et al. 2004). The
value of LRRK2 mouse models for translational research in
this direction remains to be evaluated, but primary results
indicate that these models might be useful for analyzing
impaired cellular dynamics that cause dopaminergic
dysfunction.
Models for other network perturbations in PD
Genetic models of PD are widely used. However, only a
few of these models reproduce the cardinal features of the
disease. Most strikingly, most genetically altered mice do
not show extensive or progressive loss of nigrostriatal
dopaminergic neurons (Chesselet et al. 2008). It is rea-
sonable to assume that distinct causal factors leading to
neurodegeneration in PD perturb converging molecular or
cellular pathways. In fact, the concept of PD as network
perturbation might be useful to guide translational research
(Del Sol et al. 2010). Consequently, models for network
perturbations are relevant to translational research in PD.
These include the above-mentioned genetic and toxic
models as well as models for genetic risk factors and
410 P. M. A. Antony et al.: Parkinson’s disease
123models for disease pathway perturbations such as mito-
chondrial dysfunction (Wellstead and Cloutier 2011).
Aphakia and weaver mice
Besides blindness, the so-called aphakia mice—lacking the
transcription factor Pitx3—present complete loss of
nigrostriatal dopaminergic neurons during early postnatal
development. This model does not clearly reproduce pro-
gressive loss of dopaminergic neurons in PD, yet it is
useful to validate behavioral mouse tests for dopaminergic
deﬁcits (Hwang et al. 2005). Pitx3 polymorphisms have
been associated with an increased risk for PD (Hauben-
berger et al. 2011) and may therefore be involved in human
PD. In addition, Pitx3 may directly regulate expression of
the vesicular monoamine transporter (VMAT) and the
dopamine transporter (DAT), two genes associated with
increased risk for PD (Hwang et al. 2009; Ritz et al. 2009;
Takahashi et al. 1997).
In turn, weaver mutants carry a mutation in the G-pro-
tein-coupled inwardly rectifying channel (GIRK2) (Guatteo
et al. 2004). An important characteristic of these mice for
research in PD is a gradual nigrostriatal dopaminergic
neurodegeneration (Cavalcanti-Kwiatkoski et al. 2010).
VMAT
Mice with reduced expression of VMAT, member 2
(VMAT2) have reduced monoamine storage capacity and
present both a progressive loss of striatal dopamine and
L-DOPA-responsive motor deﬁcits. In addition, VMAT2-
deﬁcient mice present progressive nonmotor signs such as
progressive deﬁcits in olfactory discrimination, delayed
gastric emptying, altered sleep latency, and age-dependent
depressive behavior. This model might be valuable for
translational research toward restoration of monoamine
dysfunction at early nonmotor stages of PD (Taylor et al.
2009).
MitoPark mice
The so-called MitoPark mouse—lacking the mitochondrial
transcription factor A (TFAM)—is a model of mitochon-
drial dysfunction in dopaminergic midbrain neurons. These
mice exhibit an adult-onset progressive loss of nigrostriatal
dopaminergic neurons, accompanied by the formation of
intraneuronal inclusions (Ekstrand and Galter 2009; Ek-
strand et al. 2007). As in human PD, impaired nigrostriatal
function precedes the onset of motor deﬁcits, and L-DOPA
administration improves motor dysfunction (Galter et al.
2010; Good et al. 2011). MitoPark mice may provide a
useful model for investigating neuroprotective strategies
(Harvey et al. 2008). However, is it not yet fully
understood whether mitochondrial dysfunction is the cause
of PD or whether it is a consequence of other perturbations
within a cascade of pathogenic events.
Aging
Aging is the primary risk factor for the development of PD.
In fact, there are many parallels between normal aging and
early stages of PD. In normal aging, the striatal dopamine
levels are reduced and there is loss of dopaminergic nigral
neurons. These losses are associated with age-related
increases in a-synuclein (Irwin et al. 1992; McNeill and
Koek 1990). Collectively, these ﬁndings suggest that aged
animals represent a useful model for the evaluation of
therapies aimed at the earliest stages of PD and that it
might be valuable to rethink aged animals’ validity for
translational research in PD.
Future challenges and needs in PD animal models
and translational research
Today, we understand that the prodrome of PD can be
initiated by genetic and environmental factors. However,
the total number of involved genes is not yet known. In
addition, different genetic backgrounds, for instance,
between different consomic mouse strains, can inﬂuence
the phenotypic outcome in animal models (Nishi et al.
2010). One challenge is, therefore, to better understand the
complex relationships between genetic factors and PD
onset and manifestation. One possibility is to identify
regions of the genome that play a role in complex
PD-related traits. In the case of PD, quantitative trait loci
(QTLs) could be used to map the genes underlying par-
kinsonian phenotypes or susceptibility to PD. The Complex
Trait Consortium has provided a reference panel of
recombinant inbred strains designed for QTL analysis
(Churchill et al. 2004; Vogel 2003). These congenic mouse
strains, generated by mating distinct inbred strains and
backcrossing the descendants, harbor nearly identical
genomes. The resulting set of populations allows the
analysis of the effects of different genetic backgrounds.
The already existing genetic PD mouse models, in contrast,
are designed to analyze the role of isolated genetic loci on a
ﬁxed background. Recently, GWAS aimed to better
understand the genetic basis underlying PD. Both QTL
analysis and whole-genome sequencing are powerful
complementary tools for proceeding with these studies.
Future therapeutic interventions will likely aim at
interrupting the progression of molecular and pathological
prodromes. However, the causal cascade of pathogenic
events is not yet fully understood. To improve the under-
standing of early pathogenesis, it will be necessary to
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the molecular, cellular, and organism scales. Furthermore,
the history of translational research in well-studied diseases
(e.g., Alzheimer disease) has demonstrated that ﬁndings
from mouse models may not always be extrapolated to
humans (Van Dam and De Deyn 2011). The validity of
animal models of human diseases will therefore need to be
evaluated. Of great importance, biomarkers found in ani-
mal models might help improve clinical risk evaluation and
early diagnosis. Furthermore, biomarkers will allow us to
empirically choose the most adequate animal models for
speciﬁc questions in translational research (Srivastava et al.
2010). Novel techniques like live cell imaging and nano-
surgery in the living mouse brain (Mascaro et al. 2010),
progress in the development of epigenetic analysis tools,
and reduced costs for omics analysis will help in the
investigation of the complexity underlying PD. The com-
plex relationships between multiple scales and evaluation
of model relevance for clinical research will require new
tools for the analysis of complex biological systems, i.e.,
systems biology, computational biology, and interdisci-
plinary cooperation. These tools should be suitable for
developing translational research into a predictive, pre-
ventive, personalized, and participatory medicine (Auffray
et al. 2010). An important step on the way to achieve
personalized medicine will be to rank the potential of
therapeutic strategies per disease state. In addition to
mouse models, other animal models, including other
rodents, primates, Drosophila melanogaster, Caenorhab-
ditis elegans, and Saccharomyces cerevisiae (Hirth 2010;
Nass et al. 2008; Witt and Flower 2006) as well as cellular
models, should be considered. The adequate choice of
models is critical for the outcome of translational research.
Conclusion
It is broadly accepted that current PD mouse models do not
adequately present typical sets of symptoms characteristic
of human PD. The striking differences between brain size
and complexity between rodents and humans limit the
direct translation of the experimental results to the clinic.
Model and species properties determine the characteristics
of the syndrome. Full reproduction of neuropathological
and clinical PD manifestations is not expected in the
mouse. However, a useful model should at least be of
mechanistic relevance, thereby allowing potential thera-
peutic testing. The awareness that many mouse models
show premotor symptoms of PD raises the possibility of
development of novel treatments. However, none of the
available models accurately recapitulates the complex and
progressive pathology that characterizes human PD. These
important shortcomings must be taken into account when
translating information from the laboratory to the clinic.
However, it is too simple to argue that the lack of reliable
models for preclinical testing undermines investigations in
clinical trials. An appropriate model should be chosen after
considering the question to be answered. The perfect model
that ﬁts all requirements does not exist. However, some of
the current models allow us to analyze precise questions
within the PD disease spectrum. At present, preclinical
models and models to evaluate enteric signs, nigrostriatal
neurodegeneration, the multiple hits hypothesis, and acute
motor dysfunction, among others, are available. In the past,
translational research has advanced using appropriate
models to aid the development of deep-brain stimulations
and L-DOPA treatments. The current trend in translational
PD research is neuroprotection or reversion of neurode-
generation. This endeavor requires models that reproduce
early pathogenic events such as those observed in trans-
genic models. Better clinical PD stratiﬁcation and identi-
ﬁcation of triggering environmental factors will further
increase the demand for targeted models. The need for
distinct model platforms and for the development of tar-
geted therapeutic interventions will grow with our knowl-
edge on PD etiology and stratiﬁcation.
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